HWM
FENC icon

HighMark Wealth Management’s Fennec Pharmaceuticals FENC Stock Holding History

HighMark Wealth Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,000
Closed -$22.5K – 587
2023
Q3 		$22.5K Hold
3,000
– – 0.02% 164
2023
Q2 		$26.5K Buy
+3,000
New +$24.9K 0.02% 159

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

HighMark Wealth Management's FENC Position: Q4 2023 in Review

HighMark Wealth Management sold out of Fennec Pharmaceuticals (FENC) in Q4 2023, closing a stake of 3,000 shares — an estimated $22.5K sold.

HighMark Wealth Management first reported a position in FENC in Q2 2023 and held it in 2 quarters. The position peaked at $26.5K in Q2 2023. 56 funds tracked by Wall St. Rank hold FENC as of Q4 2023.

  • HighMark Wealth Management reported no remaining Fennec Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • HighMark Wealth Management sold 3,000 Fennec Pharmaceuticals shares in Q4 2023, an estimated $22.5K.
  • HighMark Wealth Management first reported a position in Fennec Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • HighMark Wealth Management's Fennec Pharmaceuticals position peaked at $26.5K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2023.

Based on HighMark Wealth Management's 13F filing for Q4 2023, filed 23 Jan 2024.